Risperdal Lawsuit 2026: the $8 Billion Verdict, the $800 Million Settlement — and the New Breast-Cancer Claims

The Risperdal litigation is mostly over: Johnson & Johnson agreed to pay about $800 million in 2021 to resolve roughly 9,000 gynecomastia lawsuits, after an $8 billion jury verdict (later cut to $6.8 million) and a $2.2 billion federal settlement. In 2026, a new wave of claims alleges breast-cancer risk.

Key facts

  • The FDA approved Risperdal (risperidone) in 1993 for schizophrenia and bipolar mania in adults; in 2006 it approved the drug for irritability associated with autism in children.
  • More than 13,000 lawsuits alleged that Risperdal caused gynecomastia — the medical term for enlarged male breast tissue — in boys and young men.
  • In 2019, a Philadelphia jury awarded $8 billion in punitive damages to Nicholas Murray; a judge later reduced that award to $6.8 million.
  • In 2013, Johnson & Johnson paid $2.2 billion to resolve federal criminal and civil investigations into off-label marketing of Risperdal — one of the largest pharmaceutical settlements in U.S. history at the time.
  • In 2021, the company recorded an $800 million expense to resolve "substantially all" of the roughly 9,000 remaining U.S. gynecomastia cases.

What Risperdal is — and why children were taking it

Risperdal is the brand name for risperidone, an antipsychotic drug. The FDA first approved it in 1993 for schizophrenia and bipolar mania in adults, and in 2006 extended approval to irritability associated with autism in children. Plaintiffs' lawyers alleged that the manufacturer promoted the drug for "off-label" uses — uses the FDA had not approved, particularly in children and adolescents — while understating the risk of a hormonal side effect called gynecomastia, which is the growth of breast tissue in males. The company denied the allegations throughout the litigation.

Risperidone can raise levels of prolactin, a hormone involved in breast-tissue development, which is the mechanism plaintiffs linked to the injuries. For boys prescribed the drug over months or years, the result could be visible, lasting breast growth — and, plaintiffs argued, the psychological fallout that comes with it.

The $8 billion verdict that made headlines

The most famous number in this litigation belongs to Nicholas Murray, a Maryland man who took Risperdal between 2003 and 2008 for an autism-spectrum diagnosis. In 2015, a Philadelphia jury awarded him $1.75 million in compensatory damages — later trimmed to $680,000 — but the trial judge barred punitive damages. An appeals court reversed that limitation, opening the door to a punitive-damages phase. In October 2019, the jury came back with $8 billion in punitive damages, then the largest award among more than 13,000 Risperdal lawsuits.

The number did not survive intact. About three months later, a Philadelphia judge reduced it to $6.8 million, consistent with constitutional limits on the ratio between punitive and compensatory awards. The episode still matters for what it signaled: after years of smaller verdicts — $2.5 million for Austin Pledger in the first trial, $70 million for Andrew Yount — a jury had decided the conduct warranted a message-sized penalty.

The $2.2 billion federal case

Running in parallel was the government's case. Federal prosecutors alleged that Johnson & Johnson and its Janssen subsidiary marketed Risperdal for unapproved uses, including in children and elderly dementia patients, and paid kickbacks to doctors and pharmacies. In November 2013, the company agreed to pay $2.2 billion to resolve the criminal and civil investigations — at the time, one of the largest health-care fraud settlements in American history. The government case and the personal-injury cases were separate proceedings, but they shared the same underlying allegation: that the company pushed the drug beyond its approved uses while soft-pedaling the risks.

How the litigation ended: the $800 million resolution

By 2021, Johnson & Johnson was still facing roughly 9,000 Risperdal cases in the United States, many of them consolidated in the Philadelphia Court of Common Pleas mass-tort program, with additional cases in California and Missouri. In an SEC filing, the company disclosed a settlement in principle to resolve "substantially all" of them, recording $800 million in legal expenses in connection with the agreement. The Murray case itself was included in that resolution. Most individual settlement amounts were confidential — as is standard — so no public price list of what each plaintiff received exists.

What's new in 2026: breast-cancer-risk claims

The gynecomastia chapter is effectively closed, but a new one has opened. Attorneys now describe a developing wave of claims alleging that Risperdal use is linked to an increased risk of breast cancer, distinct from the earlier breast-growth allegations. This litigation is far earlier in its development than the gynecomastia cases: as of 2026, no publicly reported breast-cancer settlements or jury verdicts appear to exist. Because these claims rest on different alleged injuries and newer evidence, they are being evaluated on their own merits — and the statutes of limitation clock runs from when a person discovered, or should have discovered, the alleged injury.

Can you still file in 2026?

For the classic gynecomastia claims, the answer is mostly no — the bulk of that litigation was resolved in the 2021 settlement, and state statutes of limitations have long since expired for most potential plaintiffs. The realistic openings in 2026 are the newer breast-cancer-risk claims and any case where the injury was only recently discovered or diagnosed. Time limits vary sharply by state, and some states apply a "discovery rule" that starts the clock when the injury is found rather than when the drug was taken. Because these deadlines are unforgiving, anyone considering a claim should speak with a qualified attorney promptly rather than assuming time remains.

What filing a claim usually looks like

Product-liability attorneys in this field almost always work on a contingency basis, meaning there is no upfront legal fee and the attorney is paid only if the case succeeds. A case review typically requires pharmacy or medical records showing Risperdal prescriptions, records of the diagnosis, and a timeline connecting the two. Attorneys then evaluate whether the claim fits an active litigation — currently, the breast-cancer-risk claims — or whether it falls into a closed chapter. An honest evaluation costs nothing, and it is the only reliable way to know where a claim stands.

For a clear video explainer of how mass-tort pharmaceutical cases work, the Problem Solved channel covers consumer legal topics in plain language.

Related reading: Abilify Lawsuit 2026, Xarelto Lawsuit 2026, Belviq Lawsuit 2026.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

People with newer breast-cancer-risk claims tied to Risperdal. How: these claims may still be viable, especially under discovery-rule provisions, but deadlines are strict, so evaluation should not wait.

People whose injury was only recently discovered or diagnosed. How: the discovery rule can restart the clock from when the injury was learned about, which is the realistic opening left in 2026.

Families with documented Risperdal prescriptions and diagnosis records. How: prescription history and medical records are what a reviewing lawyer uses to judge whether any path remains open.

Who does not benefit:

People with classic gynecomastia claims from many years ago. How: the bulk of that litigation was resolved in the 2021 settlement of roughly 9,000 cases, and state statutes of limitations have long since expired for most potential plaintiffs.

Anyone expecting the 8 billion dollar Murray verdict amount. How: a Philadelphia judge reduced the 2019 punitive award to 6.8 million dollars, and the Murray case was later folded into the roughly 800 million dollar global resolution.

Anyone stopping risperidone because of litigation news. How: risperidone remains an FDA-approved antipsychotic, and medication changes should never be made on the basis of a lawsuit headline.

A parallel antipsychotic litigation with its own discovery-rule questions is covered in our guide to the Abilify lawsuit, where the FDA warning itself only arrived in 2016.

Frequently asked questions

Was the $8 billion Risperdal verdict ever paid?

No. A Philadelphia judge reduced the 2019 punitive award to $6.8 million, and the Murray case was later folded into the company's roughly $800 million global resolution of the gynecomastia cases.

How much did individual Risperdal plaintiffs receive?

Compensation varies widely by case, and most settlements are confidential. Publicly reported figures include $2.5 million for Austin Pledger, $70 million for Andrew Yount, and the Murray awards noted above; the 2021 resolution of about 9,000 cases was accrued at $800 million.

Is there a deadline to file a Risperdal claim?

Yes. Every state sets its own statute of limitations, and the older gynecomastia claims are largely time-barred. Newer breast-cancer-risk claims may still be viable, especially under discovery-rule provisions — but deadlines are strict, so prompt legal advice matters.

Is Risperdal still prescribed today?

Yes. Risperidone remains an FDA-approved antipsychotic prescribed for schizophrenia, bipolar mania, and irritability associated with autism, with labeling that addresses its risks. Never start or stop a prescribed medication based on litigation news; discuss any concern with your doctor.

Who benefits from filing a Risperdal claim in 2026?

People with newer breast-cancer-risk claims and people whose injury was only recently discovered benefit most, because discovery-rule provisions may still leave their claims viable even though the older gynecomastia litigation is largely closed.

Who is too late to file a Risperdal claim?

Most people with classic gynecomastia claims from many years ago are too late, because the bulk of those cases were resolved in the 2021 settlement and state statutes of limitations have expired for most potential plaintiffs.

Disclaimer: This article is general information about public litigation, not legal or medical advice. For advice about your situation, consult a qualified attorney or your doctor.

Watch on YouTube

Problem Solved on YouTube